CoChat

Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a number of patho-physiological conditions, most notably, in Huntington's disease (HD), a progressive neurodegenerative disorder. Since BDNF is also produced in blood, we have undertaken the measurement of its peripheral levels in the attempt to identify a possible link with HD prognosis and/or its progression. Here we evaluated BDNF level in 398 blood samples including 138 controls, 56 preHD, and 204 HD subjects. We found that BDNF protein levels were not reliably different between groups, whether measured in plasma (52 controls, 26 preHD, 105 HD) or serum (39 controls, 5 preHD, 29 HD). Our experience, and a re-analysis of the literature highlighted that intra-group variability and methodological aspects affect this measurement, especially in serum. We also assessed BDNF mRNA levels in blood samples from 47 controls, 25 preHD, and 70 HD subjects, and found no differences among the groups. We concluded that levels of BDNF in human blood were not informative (mRNA levels or plasma protein level) nor reliable (serum protein levels) as HD biomarkers. We also wish to warn the scientific community in interpreting the significance of changes measured in BDNF protein levels in serum from patients suffering from different conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0022966

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 BDNF protein in human plasma measured by ELISA. (A) BDNF content in plasma samples from 3 control subjects. After blood withdrawal, samples remained at RT for 1, 4, and 24 hours before the plasma was isolated (p<0.05 compared to sample processed after 1 hour, unpaired t-test). (B) BDNF protein levels in plasma samples from the French Cohort, prepared 4 hours after blood withdrawal. Control and HD subjects exhibited a large variability in plasma BDNF levels. Values inside the boxes are the medians for the group. P<0.05, controls vs early HD, P<0.05 controls vs moderate HD and P<0.05 controls vs advanced HD, according to Kruskal-Wallis test followed by Dunn's multiple comparison test (C) BDNF protein contents in plasma samples from UK Cohort A, prepared 2 hours after blood withdrawal. BDNF protein in preHD was significantly lower than that in early HD, P<0.05 according to Kruskal-Wallis test followed by Dunn's multiple comparison test.
Figure 1 BDNF protein in human plasma measured by ELISA. (A) BDNF content in plasma samples from 3 control subjects. After blood withdrawal, samples remained at RT for 1, 4, and 24 hours before the plasma was isolated (p<0.05 compared to sample processed after 1 hour, unpaired t-test). (B) BDNF protein levels in plasma samples from the French Cohort, prepared 4 hours after blood withdrawal. Control and HD subjects exhibited a large variability in plasma BDNF levels. Values inside the boxes are the medians for the group. P<0.05, controls vs early HD, P<0.05 controls vs moderate HD and P<0.05 controls vs advanced HD, according to Kruskal-Wallis test followed by Dunn's multiple comparison test (C) BDNF protein contents in plasma samples from UK Cohort A, prepared 2 hours after blood withdrawal. BDNF protein in preHD was significantly lower than that in early HD, P<0.05 according to Kruskal-Wallis test followed by Dunn's multiple comparison test.CC BY · PubMed Central
Figure 2 BDNF protein measured in human serum. (A) BDNF protein in serum from controls and subjects with preHD or HD in Italian Cohort A. (B) The samples in A were tested 1 week later. (C) BDNF levels in control and HD serum samples from the Italian Cohort B. (D) Serum BDNF content determined 3 months later. The following samples were tested: (i) thirty-nine controls, including 32 from Italian Cohort A and 7 from Italian Cohort B. From Italian Cohort A 30 had been tested previously and 2 were new samples. All those from Italian Cohort B had been tested previously; (ii) five with preHD from Italian Cohort A, including 4 samples that were previously tested and one new sample; (iii) twenty-seven with HD, including 20 out of 22 samples from Italian Cohort A and 7 samples from Italian Cohort B. Duplicate experiments were performed in parallel by two different operators (operator A, JS; operator B, BV). Operator B: BDNF protein content was undetectable in 1 preHD sample and in 3 HD samples which were excluded from data analyses.
Figure 2 BDNF protein measured in human serum. (A) BDNF protein in serum from controls and subjects with preHD or HD in Italian Cohort A. (B) The samples in A were tested 1 week later. (C) BDNF levels in control and HD serum samples from the Italian Cohort B. (D) Serum BDNF content determined 3 months later. The following samples were tested: (i) thirty-nine controls, including 32 from Italian Cohort A and 7 from Italian Cohort B. From Italian Cohort A 30 had been tested previously and 2 were new samples. All those from Italian Cohort B had been tested previously; (ii) five with preHD from Italian Cohort A, including 4 samples that were previously tested and one new sample; (iii) twenty-seven with HD, including 20 out of 22 samples from Italian Cohort A and 7 samples from Italian Cohort B. Duplicate experiments were performed in parallel by two different operators (operator A, JS; operator B, BV). Operator B: BDNF protein content was undetectable in 1 preHD sample and in 3 HD samples which were excluded from data analyses.CC BY · PubMed Central
Figure 3 Analyses of BDNF mRNA in whole blood from control and HD subjects. (A) Samples from UK Cohort B: BDNF mRNA levels normalised with GAPDH mRNA. (B) Samples from UK Cohort B: BDNF mRNA levels normalised with ß2-microglobulin (B2M) mRNA. (C) BDNF mRNA content in the same samples shown in (A) was normalised with EAR. (D) Samples from UK Cohort C: BDNF mRNA was normalised with EAR. (E) Samples from Italian Cohort C: BDNF mRNA was normalised with EAR.
Figure 3 Analyses of BDNF mRNA in whole blood from control and HD subjects. (A) Samples from UK Cohort B: BDNF mRNA levels normalised with GAPDH mRNA. (B) Samples from UK Cohort B: BDNF mRNA levels normalised with ß2-microglobulin (B2M) mRNA. (C) BDNF mRNA content in the same samples shown in (A) was normalised with EAR. (D) Samples from UK Cohort C: BDNF mRNA was normalised with EAR. (E) Samples from Italian Cohort C: BDNF mRNA was normalised with EAR.CC BY · PubMed Central
Figure 4 mRNA levels of other HD-related genes in control and HD patients. Samples are from Italian Cohort C. Blood mRNA levels of (A) ANXA1 and (B) ROCK1 were measured with two different normalisation strategies (ß-actin mRNA levels (ß-ACT), according to [25], and EAR levels, according to [24].
Figure 4 mRNA levels of other HD-related genes in control and HD patients. Samples are from Italian Cohort C. Blood mRNA levels of (A) ANXA1 and (B) ROCK1 were measured with two different normalisation strategies (ß-actin mRNA levels (ß-ACT), according to [25], and EAR levels, according to [24].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 140

Metadata

Authors
Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Lèvi, A. C., Tabrizi, S. J., Di Donato, S., & Cattaneo, E.
Affiliations
  • University of Milan (IT)
  • Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
  • National Hospital for Neurology and Neurosurgery (GB)
  • IRCCS Istituto Auxologico Italiano (IT)
Corresponding author
Cattaneo, Elena
Venue
PLoS ONE
Published
2011-08-12
Volume
6
Issue
8
Pages
e22966
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2053424572
Cited by
138
References
35
Citations by year
2026: 5 · 2025: 9 · 2024: 3 · 2023: 10 · 2022: 7 · 2021: 16 · 2020: 17 · 2019: 10 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 11 · 2012: 5
FWCI
3.58
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
Funders
  • CHDI Foundation
  • National Institute for Health and Care Research (CL-2009-18-005)
  • European Commission
  • University College London Hospitals NHS Foundation Trust
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
brain-derived neurotrophic factor, Huntington's disease, serum BDNF, plasma BDNF levels, neurodegeneration, measurement variability, disease progression
MeSH terms
Adult, Aged, Aged, 80 and over, Antidepressive Agents, Tricyclic, Benzodiazepines, Enzyme-Linked Immunosorbent Assay, Female, France, Humans, Huntington Disease, Italy, London, Male, Middle Aged, RNA, Messenger, Antipsychotic Agents, Neurotransmitter Uptake Inhibitors, Cohort Studies, Gene Expression, Annexins, Brain-Derived Neurotrophic Factor, Reverse Transcriptase Polymerase Chain Reaction, rho-Associated Kinases, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0022966
The paper
Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Lèvi, A. C., Tabrizi, S. J., Di Donato, S., & Cattaneo, E. (2011). Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0022966

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.